


**Product Name** : ADT-007  
**Cat. No.** : PC-21775  
**CAS No.** : 1945941-09-2  
**Molecular Formula** : C<sub>26</sub>H<sub>24</sub>FNO<sub>5</sub>  
**Molecular Weight** : 449.48  
**Target** : Ras  
**Solubility** : 10 mM in DMSO



CAS: 1945941-09-2

## Biological Activity

ADT-007 (ADT007) is a potent, specific **pan-RAS** inhibitor, shows potential to circumvent resistance to mutant-specific KRAS inhibitors and activates antitumor immunity.

ADT-007 displays high potency and selectivity to inhibit the growth of KRAS G13D HCT-116 cells with an IC<sub>50</sub> of 5 nM, 100 fold less sensitive to RAS WT HT-29 cells.

ADT-007 displays potency in KRAS G12C MIA PaCa-2 PDA cells, resulting in IC<sub>50</sub> values as low as 2 nM and a selectivity index approaching 1200-fold relative to RAS WT BxPC-3 PDA cells.

ADT-007 also potently inhibits the growth of three other mutant KRAS PDA cell lines with G12V or G12D mutations.

ADT-007 suppresses MIA PaCa-2 cells growth in 2D monolayer and 3D spheroid cultures with IC<sub>50</sub> values of 2.1 and 3.3 nM, respectively.

ADT-007 completely inhibits colony formation of PDA cell lines with G12C, G12D, and G12V KRAS mutations, whereas colony formation of RASWT 136 BxPC-3 cells is not significantly affected.

ADT-007 inhibits activated RAS and downstream MAPK/AKT signaling in human CRC and PDA cell lines.

ADT-007 exhibited 10x greater potency than AMG-510 in growth assays involving parental mutant KRAS G12C MIA PaCa-2 cells, also potently inhibits Lewis lung cancer (LLC) cells (NRAS Q61H) growth with IC<sub>50</sub> of 9 nM.

ADT-007 preferentially binds nucleotide-free RAS, inhibit RAS-driven cancer cell growth, activated RAS levels, and MAPK/AKT signaling.

## References

Jeremy B Foote, et al. *bioRxiv*. 2024 Jan 24:2023.05.17.541233.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com